https://www.ema.europa.eu/en/medicines/human/EPAR/truqap 2025 false false false Netherlands French English syndication feed summary of product characteristics package leaflet drug evaluation treatment outcome capivasertib capivasertib capivasertib drug approval europe adult breast neoplasms neoplasm metastasis neoplasm recurrence, local Locally Advanced Estrogen Receptor-Positive Breast Carcinoma Metastatic Estrogen Receptor-Positive Breast Carcinoma Refractory HER2-Negative Breast Carcinoma Recurrent Estrogen Receptor-Positive Breast Carcinoma PIK3CA Gene Alteration Positive AKT1 Gene Alteration Positive PTEN Gene Alteration Positive antineoplastic combined chemotherapy protocols Fulvestrant Capivasertib/Fulvestrant Regimen antineoplastic agents antineoplastic agents administration, oral risk management product surveillance, postmarketing drug interactions pregnancy breast feeding Female of Childbearing Potential AKT Inhibitor AKT Inhibitor proto-oncogene proteins c-akt Proto-Oncogene proteins c-akt3 Proto-Oncogene proteins c-akt2 Proto-Oncogene proteins c-akt1 drug evaluation, preclinical
--- https://www.has-sante.fr/jcms/p_3521945/fr/truqap-capivasertib-cancer-du-sein 2024 false false false France evaluation of the transparency committee Capivasertib capivasertib capivasertib
--- https://ansm.sante.fr/tableau-acces-derogatoire/truqap https://ansm.sante.fr/actualites/avis-de-lansm-du-07-05-2024-sur-le-medicament-truqap-160-mg-200-mg-comprimes-pellicules-dans-le-cadre-dune-demande-daap 2024 false false false France French capivasertib drug information